This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Cerner's (CERN) AbleVets Buyout to Boost Federal Services
by Zacks Equity Research
Cerner (CERN) expects to close the AbleVets deal in the fourth quarter of 2019.
Here's Why You Should Add PRA Health to Your Portfolio Now
by Zacks Equity Research
PRA Health (PRAH) is gaining steadily from expansion in international markets, solid 2019 outlook and growing CRO industry.
Here's Why You Should Add Allscripts to Your Portfolio Now
by Zacks Equity Research
Allscripts' (MDRX) focus on innovation makes it a worthy investment pick.
Here's Why You Should Retain Intuitive Surgical for Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to benefit from da Vinci surgical system, strong global foothold and solid recurring revenue base. However, margin contraction continues to raise concern.
Here's Why You Should Hold on to NextGen Healthcare for Now
by Zacks Equity Research
NextGen Healthcare (NXGN) is gaining traction from the U.S. RCM market and the growing EHR market. However, margin pressure remains a concern.
Here's Why You Should Retain Ecolab (ECL) Stock For Now
by Zacks Equity Research
Ecolab (ECL) continues to gain from robust product portfolio and strong international presence. However, forex remains a woe.
Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now
by Zacks Equity Research
PerkinElmer (PKI) is gaining steadily from the core Diagnostics segment, prudent acquisitions and margin expansion. However, forex volatility remains a concern.
Here's Why You Should Retain Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions. However, forex continues to remain a concern.
Here's Why You Should Retain DaVita (DVA) Stock for Now
by Zacks Equity Research
DaVita (DVA) is gaining steadily from expansion in international markets, strong demand in dialysis services and prudent acquisitions. However, integration risks remain a concern.
Integer Holdings (ITGR) Boosts Product Line with New Buyout
by Zacks Equity Research
Integer Holdings' (ITGR) buyout is likely to add differentiated capability for complex braided and formed biomedical structures to the company's existing product portfolio.
Here's Why You Should Invest in Surmodics (SRDX) Stock Now
by Zacks Equity Research
Surmodics (SRDX) is gaining from consistent growth In Vitro Diagnostics (IVD) unit and persistent efforts to boost R&D functionalities.
BNTGY or NNCHY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BNTGY vs. NNCHY: Which Stock Is the Better Value Option?
MEOH or NNCHY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
MEOH vs. NNCHY: Which Stock Is the Better Value Option?
CE vs. NNCHY: Which Stock Is the Better Value Option?
by Zacks Equity Research
CE vs. NNCHY: Which Stock Is the Better Value Option?
CE vs. NNCHY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CE vs. NNCHY: Which Stock Is the Better Value Option?
Cabot (CBT) Bolsters Specialty Compounds Business Globally
by Zacks Equity Research
Cabot (CBT) completes two expansion projects to increase manufacturing capacity to better serve global customers and grow in advanced polymeric materials.